Congrats to Skyhawk Therapeutics on the positive topline results from their Ph1a/b trial for the treatment of Huntington's Disease! Great news for the company as well as Huntington's patients.
Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction The Skyhawk team is delighted with the speed at which this study was conducted and thrilled to report such compelling results for SKY-0515. These topline data represent a crucial step forward for SKY-0515 and demonstrate the immense potential of the Skyhawk platform to target indications for which there are no approved disease modifying therapies. Learn More: https://lnkd.in/eYBJAnUH #HuntingtonsDisease #DrugDevelopment #Skyhawk #SmallMoleculeRNA